by Truveta Research | Jun 26, 2026 | Research
Most patients (87.1%) with evidence of oral semaglutide for obesity had evidence of their first dose at 1.5 mg, consistent with the manufacturer-recommended starting dose. Timing of dose increases closely mirrored the recommended schedule, with dose increases...
by Truveta Research | Jun 18, 2026 | Research
Authors: Nina B Masters, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Karen Gilbert Farrar, PhD ⊕Truveta, Inc, Bellevue, WA, Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA, Brianna M G Cartwright, MS ⊕Truveta, Inc, Bellevue, WA The Shingrix vaccine has been recommended for...
by Truveta Research | Jun 17, 2026 | Research
Prescribing of progesterone-containing hormone replacement therapy (HRT) more than quadrupled between 2018 and 2026. Women aged 45–54 years experienced the largest increase in prescribing, with rates increasing 488% between 2018 and 2026. By May 2026, 3% of women aged...
by Truveta staff | Jun 12, 2026 | Research
Authors: Cheng Cao ⊕,Truveta, Inc, Bellevue, WA, Ying Wei ⊕, Truveta, Inc, Bellevue, WA, Qi Li, ⊕, Iowa State University, Ames, IA, Jay Pillai ⊕ Truveta, Inc, Bellevue, WA Extracting clinical concepts from notes is essential for making electronic health record...
by Truveta staff | May 29, 2026 | Research
Authors: Sihang Zeng ⊕,Truveta, Inc, Bellevue, WA, Youngwon Kim, PhD ⊕, Truveta, Inc, Bellevue, WA, Wilson Lau, PhD ⊕, Truveta, Inc, Bellevue, WA, Ruth Etzioni, PhD ⊕, Fred Hutch Cancer Center, Seattle, WA, Meliha Yetisgen, PhD ⊕, University of Washington Seattle, WA,...
by Truveta staff | May 29, 2026 | Research
Authors: Hunter Hollis, MS ⊕ Truveta, Inc, Bellevue, WA, Amy Sullivan, MS ⊕Truveta, Inc, Bellevue, WA, Samuel Gratzl, PhD ⊕Truveta, Inc, Bellevue, WA, Jennifer Liang, MD ⊕Truveta, Inc, Bellevue, WA, Karen Gilbert Farrar, PhD ⊕Truveta, Inc, Bellevue, WA, Duy Hoang,...
